ABSTRACT
Pluripotent stem cell-derived cerebral organoids have the potential to recapitulate the pathophysiology of in vivo human brain tissue, constituting a valuable resource for modelling brain disorders, including infectious diseases. Toxoplasma gondii, an intracellular protozoan parasite, infects most warm-blooded animals, including humans, causing toxoplasmosis. In immunodeficient patients and pregnant women, infection often results in severe central nervous system disease and fetal miscarriage. However, understanding the molecular pathophysiology of the disease has been challenging due to limited in vitro model systems. Here, we developed a new in vitro model system of T. gondii infection using human brain organoids. We observed that tachyzoites can infect human cerebral organoids and are transformed to bradyzoites and replicate in parasitophorous vacuoles to form cysts, indicating that the T. gondii asexual life cycle is efficiently simulated in the brain organoids. Transcriptomic analysis of T. gondii-infected organoids revealed the activation of the type I interferon immune response against infection. In addition, in brain organoids, T. gondii exhibited a changed transcriptome related to protozoan invasion and replication. This study shows cerebral organoids as physiologically relevant in vitro model systems useful for advancing the understanding of T. gondii infections and host interactions.
KEYWORDS: Cerebral organoid, pluripotent stem cells, Toxoplasma gondii, toxoplasmosis, disease modelling
Introduction
Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii. It is a widespread disease in humans, and it has been estimated that approximately 30–50% of the world’s population is infected by this parasite [1]. The Felidae family is the only definitive host of T. gondii. These parasites undergo sexual development and reproduction in infected felines, eventually producing cysts containing formed zygotes [2].
Once T. gondii infects warm-blooded hosts, such as humans, it enters circulating cells, such as macrophages [3,4] and dendritic cells [4], enabling the parasites to cross the blood–brain barrier (BBB) within a few hours [5]. Subsequently, T. gondii preferentially forms bradyzoites, a chronic semi-dormant form of tachyzoites, and tissue cysts (containing bradyzoites) mainly in the brain [6,7]. Inside the cysts, several hundred bradyzoites remain hidden and protected from the host immune system. Thus, they can persist indefinitely in the host [8] and become the main sources of parasite transmission and pathogenesis, reactivating toxoplasmosis when the bradyzoites revert to tachyzoites [9,10]. In immunocompetent persons, toxoplasmosis is an asymptomatic infection. However, when immunodeficient patients, such as patients with AIDS or pregnant women, are infected, T. gondii can cause intracerebral mass lesions, retinochoroiditis, pneumonitis, and, occasionally, even death [11–13]. Congenital infection of T. gondii results in developmental defects in many organs. Brain tissue is one of the major organs found to have abnormalities because of multiplying parasites. Parasitic infection induces necrotic foci and profound inflammation, which may block the aqueduct of Sylvius and cause hydrocephalus of the lateral ventricles. These foci also calcify. The classic features related to brain developmental defects are mental retardation, seizures, microcephalus, hydrocephalus, cerebral calcifications, and abnormal cerebrospinal fluid [11,14].
More recently, many reports have suggested that there are unrecognized consequences in humans infected with T. gondii, such as impulsive and aberrant neurocognitive behaviour and psychiatric illnesses, including schizophrenia [15,16]. Although several drugs, including azithromycin, clarithromycin, spiramycin, atovaquone, dapsone and cotrimoxazole, have been used for the treatment of toxoplasmosis, but their effect in eliminating tissue cysts and bradyzoites has been unsatisfactory [17]. Further, there is no approved vaccine against toxoplasmosis [18,19].
The main challenge in the research of T. gondii-host interactions and drug development is the lack of an optimal in vitro model that could efficiently recapitulate T. gondii infection in humans. Several studies have used 2D cultures of microglia, astrocytes, and neuron cell lines as T. gondii in vitro model systems and demonstrated that these brain cell lines were susceptible to infection [20]. However, in most cases, the T. gondii infection was sustained for a short time and showed incomplete expansion [21]. In addition, the monolayer environmental condition is considerably different than that of a physiological 3D system, which may alter infectious processes, such as invasion, replication, and egression. A recent study showed that Vero cells in a 3D culture system showed a more consistent shape and proliferation pattern of T. gondii than was exhibited by a 2D culture system [21]. However, a 3D culture system based on a single cell type cannot fully recapitulate host–T. gondii interactions or lead to the determination of specific cell type-dependent host–parasite interactions [21].
Organoids have recently emerged as experimental tools for disease modelling, drug screening, regenerative medicine, and host–microbe interactions [22]. An organoid is a self-organizing stem cell-derived 3D structure consisting of organ-specific cells [23]. In contrast to monolayer culture systems, organoids resemble original tissues in terms of structural features, functionality, and genetic signatures [24]. By exploiting these similarities, we can perform research on diseases in organs and tissues that are not readily accessible because of their anatomic locations, such as the brain.
In the present study, we infected cerebral organoids with T. gondii tachyzoites and demonstrated that tachyzoites differentiated into bradyzoites, which replicated in parasitophorous vacuoles to form tissue cysts within the organoids. Our study sought to determine whether cerebral organoids infected with T. gondii recapitulate the human brain and can be used as model systems to understand T. gondii–host interactions.
Materials and methods
Cerebral organoid generation and culture
To generate cerebral organoids, we slightly modified the methods previously described by Lancaster et al. [25,26]. The H9 (WA09) human embryonic stem cell line, obtained from WiCell (Madison, WI, USA), was grown in mTeSR1 (Stem Cell Technologies, Vancouver, Canada) on a Matrigel-precoated plate (Corning, NY, USA), and the medium was changed every day. Colonies were detached from the Matrigel-coated plate using ReLeSR (Stem Cell Technologies), and 9000 cells were transferred to a round-bottom 96-well plate filled with AggreWell medium and 10% Clone R (Stem Cell Technologies). After 2 d, the medium was replaced with fresh AggreWell without Clone R, and the cells were incubated for an additional 3 d. On day 6, the medium was replaced with neural induction medium (NIM) containing DMEM/F12, N2 supplement (Thermo Fisher Scientific, Waltham, MA, USA), minimum essential medium-nonessential amino acids (MEM-NEAAs), GlutaMAX (Thermo Fisher Scientific) and 1 μg/ml heparin (Sigma, MO, USA), and the cells incubated for 5 d. On day 6, after the NIM medium was changed, embryoid bodies (EBs) were transferred by pipette onto Matrigel (Corning) droplets that were 3 mm in diameter. These droplets were incubated for 1 h at 37°C, transferred to 24-well plates and maintained in cerebral organoid differentiation medium (CORD) containing DMEM/F12, Neurobasal (Gibco), N2 supplement, NEAA (Gibco), an insulin solution (Sigma), the penicillin streptomycin (Sigma), GlutaMAX, β-mercaptoethanol (Gibco) and B-27 (without vitamin A) (Thermo Fisher Scientific) for 3 d. After 3 d, the medium was replaced with cerebral organoid differentiation medium containing vitamin A (CORDA), DMEM/F12, Neurobasal, N2 supplement, NEAA, an insulin solution, GlutaMAX, β-mercaptoethanol, and B-27 (with vitamin A) (Gibco) and maintained on a spinning bioreactor (N-BIOTEK). The medium was replaced every 3 d.
Toxoplasma gondii culture
Tachyzoites of the T. gondii PTG-GFP 5 S65 T, haplogroup 2, ME49 strain (50941, ATCC, Manassas, VA, USA) and those of the T. gondii RH-GFP strain were maintained in vitro using Vero cells (CCL-81, ATCC) cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco) at 37°C in a humidified incubator with an atmosphere of 5% CO2. T. gondii were allowed to replicate for 3 d in Vero cells homogenized with 1 mL of Dulbecco's phosphate-buffered saline (Gibco/Life Technologies, Grand Island, NY, USA) using a 23-gauge needle. The tachyzoites of the T. gondii RH strain that expresses transgenic green fluorescent protein (RH-GFP) were provided by Dr. Yoshifumi Nishikawa (Obihiro University of Agriculture and Veterinary Medicine, Japan).
Organoid infection and live imaging
Initially, the medium in which the cerebral organoids was maintained was removed, and pre-chilled Cell Recovery solution (Corning) was added. Using a wide-bore tip, the solution was pipetted up and down, and the Matrigel was carefully removed to avoid damaging the organoids. Then, the cell culture plates were incubated at 4°C for 20 min. When the organoids were free from the Matrigel, they were washed three times with PBS and then fresh media were added. Next, 1 × 103 ME49 tachyzoites and RH tachyzoites were incubated with separate cerebral organoids, each in a well with 200 μl of culture medium, in a 96-well plate for 4 h at 37°C in a humidified incubator with an atmosphere of 5% CO2. After 4 h, the cerebral organoids were washed three times with PBS and fresh medium was added.
For live-cell imaging, GFP-tagged T. gondii-infected organoids were transferred to a 35-mm dish, and fresh medium was added. The organoids were maintained at 37°C in an automated microscope chamber with a humidified atmosphere of 5% CO2 (BioTek Lionheart FX, BioTek Instruments, Winooski, VT, USA). Time-lapse images were acquired every 30 min for a total of 50 h. In total, nine positions were imaged, and a z-stacking process was performed.
RNA isolation and RNA-seq analysis
RNA was extracted using the RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The library was prepared using the TruSeq Stranded mRNA LT Sample prep kit (Illumina, San Diego, CA, USA) and run on a HiSeq 4000 sequencer (Illumina) with a 101-bp paired-end read length. Raw data were processed using HISAT2 [27] to align genome reads with reference genomes (hg19 for humans and GCF_000006565.2_TGA4 for the ME49 strain of T. gondii).
Histology and immunofluorescence staining
Cerebral organoids were fixed overnight in 4% paraformaldehyde at 4°C. The following day, the Matrigel was removed, and the organoids were incubated in fresh 4% paraformaldehyde for 1 h at 4°C. Subsequently, the organoids were allowed to sink in a 30% sucrose solution at 4°C and then were embedded in optimal cutting temperature (OCT) compound (Scigen, Gardena, CA, USA) and incubated at −80°C for 1 d. Thereafter, the organoids were cryosectioned into 20-μm-thick sections, permeabilized in 0.3% Triton X-100, and blocked with a 3% bovine serum albumin solution for 1 h. The sections were then incubated overnight with primary antibodies at 4°C. The following antibodies were used in this study: anti-SOX2 (AB5603, Sigma), anti-PAX6 (MA1-109, Invitrogen, Carlsbad, CA, USA), anti-SATB2 (ab34735, Abcam), anti-O4 (MAB1326, R&D system, MN, USA), anti-O1 (MAB1327, R&D system), anti-GFAP (ab7260, Abcam) anti-DAPI (D1306, Invitrogen), and anti-TUJ1 (801202, BioLegend, San Diego, CA, USA). The following secondary antibodies were purchased from Invitrogen: Alexa Fluor 594 (A21207 and A21203) and Alexa Fluor 488 (A21206 and 21202). Immunofluorescence was detected by confocal microscopy (LSM800; Carl Zeiss, Oberkochen, Germany), and analysis was performed using ZEN 2 blue edition software (Carl Zeiss).
Ingenuity pathway analysis (IPA)
To predict the possible diseases and disorders in the ME49- and RH-infected cerebral organoids, differentially expressed genes were evaluated by ingenuity pathway analysis (IPA) (Ingenuity Systems, Redwood City, CA, USA). A p-value of less than 0.05 was considered significant.
Enzyme-linked immunosorbent assay (ELISA) for T. gondii
Serum obtained from C57BL/6 mice infected with T. gondii tachyzoites was assayed by enzyme-linked immunosorbent assay (ELISA) using antibodies against the T. gondii P30 protein with a Multispecies ID Screen® Toxoplasmosis Indirect kit (IDVET, Montpellier, France) following the manufacturer’s instructions. The serum was diluted 1:9 with dilution buffer and incubated for 1 h at room temperature. The plates were rinsed three times with washing buffer, after which horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (Sigma, St. Louis, MO, USA) was added, and then, the plates were incubated for 1 h at room temperature. After the final washing, substrate solution was added to each well and incubated for 15 min at room temperature in the dark. The reaction was stopped using 0.5 M H2SO4 solution, and the absorbance was read at 450 nm using an ELISA reader. Mean OD values > 0.5 were defined as positive [28].
Transmission electron microscopy
Organoids were primarily fixed overnight with Karnovsky’s fixative (2% glutaraldehyde and 2% paraformaldehyde in 0.5 M cacodylate buffer, Electron Microscopy Sciences, Hatfield, PA, USA) at 4°C and post fixed with 1 M osmium tetroxide (diluted in 0.1 M sodium cacodylate buffer). After dehydration in a series of gradient ethanol solutions, the samples were subjected to propylene oxide and then polymerized using Spurr’s resin (Electron Microscopy Sciences, Hatfield, PA, USA). The samples were subsequently cut into 70-nm-thick slices and loaded onto a 2 × 1 mm CU grid coated with Formvar/carbon film (Electron Microscopy Sciences, Hatfield, PA, USA). Transmission electron microscopy (TEM) images were obtained using a TEM microscope (80 kV) (JEOL, TYO, JAPAN).
Statistical analysis
The quantitative data are presented as the means ± S.E.M. based on at least 3 independent experiments. For statistical analysis, Student’s t-test was used to compare two experimental groups, and for comparisons of more than 3 groups, one-way ANOVA with Bonferroni correction was performed with GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA). A p-value of less than 0.05 was considered statistically significant.
Results
In vitro generation of cerebral organoids from human embryonic stem cells
To generate cerebral organoids, we modified the previously reported methods described by Lancaster et al. [25,26]. Briefly, we seeded 9000 cells in each round-bottom well of a 96-well plate to generate uniformly sized embryoid bodies (EBs). After 5–7 d, we confirmed that the EBs were of similar sizes (Fig. S1A and S1B). Next, the EBs were maintained in neural induction medium for 5 d to generate neuroectodermal tissue, and a Matrigel droplet was embedded into each well to provide a scaffold. Plate cultures containing these Matrigel droplets were then placed on an orbital shaker to increase oxygen-nutrient absorption (Figure 1A, B and S2). To test whether cerebral organoids mimic key structural features of the human brain, histological analysis was performed. On day 50 of differentiation, cerebral organoids were stained for specific markers of a diverse set of brain cell types. We observed bipolar-shaped SRY-Box 2 (SOX2)+/paired box 6 (PAX6)+/progenitor cell populations in the ventricular zone. In addition, a large number of cells expressing the lower-layer cortical neuronal marker COUP TF1-interacting protein 2 (CTIP2) were detected as cortical plate (CP)-like structures. Neuron-specific class III beta-tubulin (TUJ1)+ neuronal layer GFP-positive cells were also found in the highly proliferating neuronal cell layer (Figure 1C). Furthermore, on day 55, glial fibrillary acidic protein (GFAP)+ astrocytes and O4+ oligodendrocytes started to appear, and by day 70, a large number of GFAP+ and O4+ cells were observed in the cerebral organoids (Figures 1C, S3 and S4).
Infection of human cerebral organoids with T. gondii
Although T. gondii infection has been reported in 2D cell cultures, the transformation of T. gondii tachyzoites to bradyzoites, which is a central event of chronic toxoplasmosis infection (Figure 2A) and constitutes a life-long risk for recurring infection [11], has not been studied in vitro. Thus, we sought to determine whether cerebral organoids can be used as an in vitro models for T. gondii infection. To investigate whether parasites entered and were sustained in the human cerebral organoids, tachyzoites from two T. gondii strains, the type I (RH) strain expressing green fluorescent protein (RH-GFP) and the type II strain (ME49) also expressing green fluorescent protein (ME49-GFP), were incubated with cerebral organoids for 4 h. As shown in Figure 2B, GFP signals were detected within the organoids 2 days post-infection in the ME49-infected cerebral organoids. To study this signalling in more detail, we set up a live-imaging experiment using fluorescent microscopy of cerebral organoids 1 d after ME49 infection (Movie S1). We initially observed that the T. gondii cells invaded the surface of the organoid. However, by day 27, the parasites had propagated within the cerebral organoid, as shown by the GFP-positive signals throughout the cerebral organoid (Figure 2B).
Next, we examined whether T. gondii preferentially infects specific brain cells, such as neuronal cells, neuronal progenitor cells, astrocytes, oligodendrocytes. ME49-GFP infected (COME49) and RH-GFP infected (CORH) cerebral organoids were fixed at 3 days post-infection and stained for cell-type specific markers. We found that T. gondii (green) was co-detected with TUJ1, a neuronal marker; GFAP, a marker of astrocytes; and O1, a marker of oligodendrocytes. These findings indicated that the ME49 and RH strains preferentially infected these cell types in the cerebral organoids (Figure 2C, D and E). In contrast, none of the T. gondii strains colocalized with SOX2, a marker of radial glial cells (Figure 2F).
T. gondii form cysts in cerebral organoids
In intermediate hosts, T. gondii can form tissue cysts (bradyzoites), which persist throughout the life of the host [11]. In addition, bradyzoites in tissue cysts can dedifferentiate into tachyzoites, representing the replicative stage (Figure 2A). To address whether T. gondii can replicate within the organoids, we first examined the cyst-like formations of densely packed T. gondii in the cerebral organoids. We observed that by 5 days post-infection, both T. gondii strains had formed tissue cyst-like structures within the cerebral organoids enveloped by TUJ1-positive cells (Figure 3A and B). To ascertain the developmental stages of these T. gondii in the organoids, we performed TEM imaging and observed a diverse number of bradyzoites, which were characterized by the presence of amylopectin granules (Am) located inside the parasitophorous vacuole membranes (PVMs). This observation indicates that T. gondii shows interconversion between the rapidly growing tachyzoite and latent encysted bradyzoite stages, recapitulating the complex life cycle stages of the parasite within the organoids (Figure 3C, D, and E).
T. gondii exhibit virulence in cerebral organoids
We evaluated whether T. gondii parasites in infected organoids remained virulent. To examine T. gondii virulence in the organoids, we mechanically dissociated infected organoids and introduced them into mice through intraperitoneal injection. After two months, mouse serum was collected, and antibodies against the T. gondii P30 protein were measured (Figure 4A). We observed a 3.4- to 10.4-fold (p-value < 0.05) increase in the level of T. gondii P30 protein in the COME49-injected mice and a 2.4- to 4.4-fold (p-value < 0.05) increase in the CORH-injected mice, compared to the noninfected mice (Figure 4B and C).
Transcriptomic analyses of T. gondii and infected organoids
Next, we performed a transcriptome-sequencing analysis of the ME49 strain of T. gondii 0 and 72 h post-infection. Hierarchical clustering of the differentially expressed genes (DEGs) (|fc| ≥ 2, raw p-value < 0.05) showed that three independent ME49 genes were clustered separately at 0 and 72 h post-infection (Fig. S5). We identified 786 genes, of which 402 genes were upregulated and 384 genes were downregulated, 72 h post-infection. (Figure 5A and B, Fig. S5, Table S1; |fc| ≥ 2, raw p-value < 0.05). We found that ribosomal proteins, such as ribosomal protein S20 (RPS20), S14 (RPS14), L15 (RPL15), and S14 precursors, which are generally expressed in bradyzoites [29], were highly expressed in the ME49 strain 72 h post-infection, indicating bradyzoite formation in the brain organoids. Moreover, rhoptry organelle proteins (ROPs) were elevated in the post-infected ME49 strain, indicating the potential ME49 invasion and establishment of the replicative niche in the parasitophorous vacuoles in the brain organoid cells [30,31]. Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) analyses were conducted on the DEGs from 72 h post-infected ME49 strain. Toxoplasmosis was predicted by the KEGG analysis, suggesting that transcriptomic changes to the ME49 strain in the infected brain organoids recapitulated toxoplasmosis (Figure 5C). The GO analysis predicted that both threonine-type endopeptidase activity-related processes and proteasome core complexes, which are involved in host cell invasion of apicomplexan parasites, particularly T. gondii [32], would be increased in the ME49 strain in the infected brain organoids compared to their predicted occurrence in tachyzoites (Figure 5D).
Next, we performed transcriptomic analysis of the cerebral organoids after 72 h of T. gondii infection. The heat map of the one-way hierarchical clustering using z-scores for normalized values (|fc| ≥ 2, raw p-value < 0.05) showed that all three independent samples of CO, COME49, and CORH (Fig. S6A and S6B) were clustered together. Our results revealed that 25 and 38 DEGs were identified in the COME49 and CORH, respectively (Figure 6A and B). Type I IFN contributes to the modulation of chronic T. gondii persistence in the central nerve systems [33,34]. Our study supported the observation that the type I IFN signalling pathway was highly altered by T. gondii infection in both of the strains analyzed by GO (Figure 6C and D). We additionally identified the top five DEGs in both the COME49 (interferon alpha-inducible protein 6 (IFI6), signal transducer and activator of transcription 1 (STAT1), cortexin-1 (CTXN1), actin-related protein 2/3 complex subunit 5 (ARPC5), and synaptophysin-like 1 (SYPL1)) and CORH (IFI6, interferon-induced transmembrane protein 1 (IFITM1), lymphocyte antigen 6 family member E (LY6E), CTXN1, and dynactin subunit 4 (DCTN4)) models (Figure 6E and F; |fc| ≥ 2, raw p-value < 0.05) were related to type 1 IFN signalling. Next, to validate the activation of the type I IFN signalling pathway during T. gondii infection, we conducted qPCR analysis. The expression of the representative genes of the type I IFN signalling pathway (IL-10, TNF-α, IFN-α, and ISG15) was increased in the T. gondii-infected organoids (Fig. S7). Subsequently, we applied ingenuity pathway analysis (IPA) to predict the functions and disease outcomes in the cerebral organoids following T. gondii infection. The top three infection outcomes identified in the COME49 were antiviral response, necrosis, and psoriasis, whereas the top three outcomes in the CORH were innate-immune response, multiple-sclerosis, and neuromuscular disease (Fig. 6G).
Discussion
In this study, we evaluated the possibility of using human embryonic stem cell-derived cerebral organoids as an in vitro model systems for studying T. gondii infections. Until now, the research on T. gondii infection has highly relied on 2D cell culture conditions or studies on animals, such as rodents. Although one study has been reported regarding the study of T. gondii infection in a 3D cell line culture system consisting of a collagen matrix, the model was unable to recapitulate the tissue complexity in terms of diverse cell types, conditions and interactions between the host and the parasites [21].
Here, we generated cerebral organoids and infected them with two GFP-tagged T. gondii strains (ME49GFP and RHGFP) to assess whether our T. gondii-infected cerebral organoids could recapitulate the in vivo human brain system. Accordingly, we investigated the distribution of T. gondii within the organoids. The immunofluorescence data revealed that T. gondii showed mainly preferential targeting to neuronal cells, astrocytes, and oligodendrocytes but not to radial glial cells in the cerebral organoid culture system. T. gondii infects nucleated cells, such as neurons, astrocytes, and glial cells, in rodents [35,36]. Despite this recapitulation, the cell type sensitivity of the T. gondii infection has not been sufficiently characterized in toxoplasmosis patients or in 3D human cell culture systems. One recent study reported on the prevalence of T. gondii in a series of human autopsy samples, and the authors stated that T. gondii was detected in the neurons and astrocytes in the brains of these toxoplasmosis patients [37], findings consistent with our data. Regarding radial glial cells, one report demonstrated that T. gondii can infect rodent radial glial cells [38]; however, the considerable differences between humans and other species is notable. To date, it is not known whether human radial glial cells are susceptible to T. gondii. However, T. gondii infection models of brain organoids provided evidence suggesting that radial glial cells are not the main targeted cell type, with T. gondii displayed higher preferentiality infecting differentiated neuronal cells. Given the lack of data on human cells, we can only speculate that the observed lack of T. gondii infectivity in radial glial cells is due to a species-type-dependent effect. However, to verify the mechanism by which radial glial cells escape T. gondii infection in 3D culture systems and to quantify the selective tropism of T. gondii in cerebral organoids, further studies are required.
Next, we aimed to show the formation of tissue cyst-like structures in T. gondii in the cerebral organoids. Using immunofluorescence staining, we observed densely packed bradyzoites located in the neuronal cells of the cerebral organoids. Our TEM images of an organoid infected with tachyzoites also revealed the presence of parasitophorous vacuoles (PV) surrounding intracellular tachyzoites and cyst-like structures. Because tachyzoites can differentiate into bradyzoites in the host cell and form tissue cysts [37], we speculated that T. gondii efficiently simulated its asexual life cycle and converted between its tachyzoite and bradyzoite stages in the cerebral organoids. Moreover, the T. gondii strains isolated for the present study showed similar immunological responses in mice [39]. Of immunological interest, although the RH strain has high virulence, the antibodies in the COME49-injected mice were higher than they were in the CORH-injected mice. However, the reason for the immunological difference was not found, and may be due to differences in the P30 protein. Further studies to determine immunological differences between the two strains should be conducted in a brain organoid 3D culture system.
RNA-sequencing data revealed the host–pathogen interaction responses of both T. gondii strains examined in infected human cerebral organoids. Despite the two different strains by which the cerebral organoids were infected, we observed that, in both cases, type I interferon (IFN-I) was an important cytokine in the immune response to the parasitic infection [40]. Interferon is an important cytokine in innate immune responses to parasitic infections. In T. gondii-infected mice, IFN-I was detected in the serum, spleen, and brain, and IFN-I expression gradually increased as the infection progressed [41–44]. One of the limitations of the cerebral organoids in this study was caused by the lack of innate immune cells, such as microglia and dendritic cells (DCs). In vivo studies have revealed that the proinflammatory cytokine IL-12 is stimulated by DCs and macrophages, thus inducing natural killer (NK) and NK T cells to release IFN gamma, resulting in the activation of antimicrobial machinery. In addition, DCs and macrophages present parasite antigens and costimulatory molecules that subsequently prime T cells [31]. According to the IPAs based on the DEGs and downstream effects in T. gondii-infected cerebral organoids, type I interferon, antiviral and innate immune responses were detected. However, IL-12-related immune responses were not detected in either the ME49- or RH-infected cerebral organoids. To improve the model system, the presence of major innate immune cells during organoid development is necessary.
Interestingly, cerebral organoids infected with the RH strain showed an increase in factors associated with multiple sclerosis (MS). It was reported that T. gondii and MS were negatively correlated [45]. However, Yaman et al. suggested that exposure to T. gondii may be one of the causes of MS development [46]. These contradicting reports indicate that the relationship between T. gondii and MS remains controversial. Our results implied that modelling T. gondii infection in cerebral organoids may allow for the investigation in-depth mechanisms of specific diseases related to T. gondii infection.
In summary, in this study, we evaluated the possibility of disease modelling for T. gondii infection using human cerebral organoids. We observed that tachyzoites were able to differentiate into bradyzoites and form cyst-like structures, indicating that the asexual life cycle and stage conversion of T. gondii were effectively simulated in our organoid culture system. We also revealed that a specific strain does not preferentially infect the brain. T. gondii transcriptomic analysis revealed gene expression changes upon organoid infection with T. gondii, which enabled the prediction of the biological process of T. gondii in the human brain organoids. In conclusion, we believe that the 3D cerebral organoids can be physiologically relevant model systems useful for understanding T. gondii infection.
Supplementary Material
Acknowledgments
This work has been supported by KCDC grants 2017-NG61004-00, 2017-NC61001-00 and 2017-4837-311. The use of embryonic stem cells was approved by the IRB of Korea Centers for Disease Control and Prevention: approval number 2018-06-01-P-A, 2017-03-07-C-A. We thank Hyun Jung Choi (Core Lab., Division of Biosafety Evaluation and Control, KNIH) for the confocal imaging service. We thank Seoul National University for providing us with the Transmission Electron Microscope Core service. We also warmly thank Dr. Yoshifumi Nishikawa (Obihiro University of Agriculture and Veterinary Medicine, Japan) for kindly providing tachyzoites of the T. gondii RH strain that expresses transgenic green fluorescent protein.
Correction Statement
This article has been republished with minor changes. These changes do not impact the academic content of the article.
Funding Statement
This work has been supported by Korea Centers for Disease Control and Prevention (KCDC) grants [grants numbers 2017-NG61004-00, 2017-NC61001-00 and 2017-4837-311].
Disclosure statement
No potential conflict of interest was reported by the author(s).
References
- 1.Flegr J, Prandota J, Sovickova M, et al. . Toxoplasmosis–a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PloS One. 2014;9(3):e90203–]. doi: 10.1371/journal.pone.0090203 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hofer U. The cat is out the bag about Toxoplasma host range. Nat Rev Microbiol. 2019 Nov;17(11):646–647. doi: 10.1038/s41579-019-0266-6 [DOI] [PubMed] [Google Scholar]
- 3.Da Gama LM, Ribeiro-Gomes FL, Guimaraes Jr U, et al. . Reduction in adhesiveness to extracellular matrix components, modulation of adhesion molecules and in vivo migration of murine macrophages infected with Toxoplasma gondii. Microbes Infect. 2004 Nov;6(14):1287–1296. doi: 10.1016/j.micinf.2004.07.008 [DOI] [PubMed] [Google Scholar]
- 4.Courret N, Darche S, Sonigo P, et al. . CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood. 2006 Jan 1;107(1):309–316. doi: 10.1182/blood-2005-02-0666 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pittman KJ, Knoll LJ.. Long-Term relationships: the complicated Interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections. Microbiol Mol Biol Rev: MMBR. 2015 Dec;79(4):387–401. doi: 10.1128/MMBR.00027-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lambert H, Barragan A.. Modelling parasite dissemination: host cell subversion and immune evasion by Toxoplasma gondii. Cell Microbiol. 2010 Mar;12(3):292–300. doi: 10.1111/j.1462-5822.2009.01417.x [DOI] [PubMed] [Google Scholar]
- 7.Harker KS, Ueno N, Lodoen MB.. Toxoplasma gondii dissemination: a parasite's journey through the infected host. Parasite Immunol. 2015 Mar;37(3):141–149. doi: 10.1111/pim.12163 [DOI] [PubMed] [Google Scholar]
- 8.Ferreira da Silva Mda F, Barbosa HS, Gross U, et al. . Stress-related and spontaneous stage differentiation of Toxoplasma gondii. Mol Biosyst. 2008 Aug;4(8):824–834. doi: 10.1039/b800520f [DOI] [PubMed] [Google Scholar]
- 9.Tenter AM, Heckeroth AR, Weiss LM.. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000 Nov;30(12-13):1217–1258. doi: 10.1016/S0020-7519(00)00124-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Montoya JG, Liesenfeld O.. Toxoplasmosis. Lancet. 2004 Jun 12;363(9425):1965–1976. doi: 10.1016/S0140-6736(04)16412-X [DOI] [PubMed] [Google Scholar]
- 11.Robert-Gangneux F, Darde ML.. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012 Apr;25(2):264–296. doi: 10.1128/CMR.05013-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bergin C, Murphy M, Lyons D, et al. . Toxoplasma pneumonitis: fatal presentation of disseminated toxoplasmosis in a patient with AIDS. Eur Respir J. 1992 Sep;5(8):1018–1020. [PubMed] [Google Scholar]
- 13.Patil HV, Patil VC, Rajmane V, et al. . Successful treatment of cerebral toxoplasmosis with cotrimoxazole. Indian J Sex Transm Dis AIDS. 2011 Jan;32(1):44–46. doi: 10.4103/0253-7184.81255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.McAuley JB. Congenital toxoplasmosis. J Pediatric Infect Dis Soc. 2014 Sep;3(Suppl 1):S30–S35. doi: 10.1093/jpids/piu077 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Flegr J. Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J Exp Biol. 2013 Jan 1;216(Pt 1):127–133. doi: 10.1242/jeb.073635 [DOI] [PubMed] [Google Scholar]
- 16.Webster JP, Kaushik M, Bristow GC, et al. . Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour? J Exp Biol. 2013 Jan 1;216(Pt 1):99–112. doi: 10.1242/jeb.074716 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Montazeri M, Mehrzadi S, Sharif M, et al. . Drug resistance in Toxoplasma gondii. Front Microbiol. 2018;9:2587. doi: 10.3389/fmicb.2018.02587 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Montazeri M, Mehrzadi S, Sharif M, et al. . Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review. Parasitol Res. 2018 Oct;117(10):3045–3057. doi: 10.1007/s00436-018-6027-z [DOI] [PubMed] [Google Scholar]
- 19.Montazeri M, Sharif M, Sarvi S, et al. . A systematic review of In vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006-2016). Front Microbiol. 2017;8:25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mendez OA, Koshy AA.. Toxoplasma gondii: entry, association, and physiological influence on the central nervous system. PLoS Pathog. 2017 Jul;13(7):e1006351. doi: 10.1371/journal.ppat.1006351 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Danielson JJ, Perez N, Romano JD, et al. . Modelling Toxoplasma gondii infection in a 3D cell culture system In vitro: Comparison with infection in 2D cell monolayers. PloS One. 2018;13(12):e0208558. doi: 10.1371/journal.pone.0208558 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Heo I, Dutta D, Schaefer DA, et al. . Modelling cryptosporidium infection in human small intestinal and lung organoids. Nature Microbiology. 2018 Jul;3(7):814–823. doi: 10.1038/s41564-018-0177-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Lancaster MA, Knoblich JA.. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014 Jul 18;345(6194):1247125. doi: 10.1126/science.1247125 [DOI] [PubMed] [Google Scholar]
- 24.Dutta D, Heo I, Clevers H.. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017 May;23(5):393–410. doi: 10.1016/j.molmed.2017.02.007 [DOI] [PubMed] [Google Scholar]
- 25.Lancaster MA, Renner M, Martin CA, et al. . Cerebral organoids model human brain development and microcephaly. Nature. 2013 Sep 19;501(7467):373–379. doi: 10.1038/nature12517 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Allende ML, Cook EK, Larman BC, et al. . Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation. J Lipid Res. 2018 Mar;59(3):550–563. doi: 10.1194/jlr.M081323 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kim D, Langmead B, Salzberg SL.. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015 Apr;12(4):357–360. doi: 10.1038/nmeth.3317 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hong SH, Lee SE, Jeong YI, et al. . Prevalence and molecular characterizations of Toxoplasma gondii and Babesia microti from small mammals captured in Gyeonggi and Gangwon Provinces, Republic of Korea. Vet Parasitol. 2014 Oct 15;205(3-4):512–517. doi: 10.1016/j.vetpar.2014.07.032 [DOI] [PubMed] [Google Scholar]
- 29.Chen LF, Han XL, Li FX, et al. . Comparative studies of Toxoplasma gondii transcriptomes: insights into stage conversion based on gene expression profiling and alternative splicing. Parasit Vectors. 2018 Jul 11;11(1):402. doi: 10.1186/s13071-018-2983-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Denkers EY, Bzik DJ, Fox BA, et al. . An inside job: hacking into Janus kinase/signal transducer and activator of transcription signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect Immun. 2012 Feb;80(2):476–482. doi: 10.1128/IAI.05974-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Hunter CA, Sibley LD.. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol. 2012 Nov;10(11):766–778. doi: 10.1038/nrmicro2858 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kim K. Role of proteases in host cell invasion by Toxoplasma gondii and other Apicomplexa. Acta Trop. 2004 Jun;91(1):69–81. doi: 10.1016/j.actatropica.2003.11.016 [DOI] [PubMed] [Google Scholar]
- 33.Mitsunaga T, Norose K, Aosai F, et al. . Infection dynamics of Toxoplasma gondii in gut-associated tissues after oral infection: The role of Peyer's patches. Parasitol Int. 2019 Feb;68(1):40–47. doi: 10.1016/j.parint.2018.08.010 [DOI] [PubMed] [Google Scholar]
- 34.Matta SK, Olias P, Huang Z, et al. . Toxoplasma gondii effector TgIST blocks type I interferon signaling to promote infection. Proc Natl Acad Sci USA. 2019 Aug 27;116(35):17480–17491. doi: 10.1073/pnas.1904637116 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Halonen SK, Lyman WD, Chiu FC.. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J Neuropathol Exp Neurol. 1996 Nov;55(11):1150–1156. doi: 10.1097/00005072-199611000-00006 [DOI] [PubMed] [Google Scholar]
- 36.Creuzet C, Robert F, Roisin MP, et al. . Neurons in primary culture are less efficiently infected by Toxoplasma gondii than glial cells. Parasitol Res. 1997;84(1):25–30. doi: 10.1007/s004360050351 [DOI] [PubMed] [Google Scholar]
- 37.Alvarado-Esquivel C, Sanchez-Anguiano LF, Mendoza-Larios A, et al. . Prevalence of Toxoplasma gondii infection in brain and heart by immunohistochemistry in a hospital-based autopsy series in Durango, Mexico. Eur J Microbiol Immunol (Bp). 2015 Jun;5(2):143–149. doi: 10.1556/1886.2015.00014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Adesse D, Marcos AC, Siqueira M, et al. . Radial Glia cell infection by Toxoplasma gondiidisrupts brain microvascular endothelial cell integrity. bioRXiv. 2018:378588. [Google Scholar]
- 39.Bulow R, Boothroyd JC.. Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J Immunol. 1991 Nov 15;147(10):3496–3500. [PubMed] [Google Scholar]
- 40.Silva-Barrios S, Stager S.. Protozoan parasites and type I IFNs. Front Immunol. 2017;8(14). doi: 10.3389/fimmu.2017.00014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Omata Y, Yagami K, Sakurai H, et al. . Interferon induction in Toxoplasma gondii infected mice. Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene 1 Abt Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie. Int J Microbiol Hyg A, Med Micro. 1983 Sep;255(2-3):392–396. [PubMed] [Google Scholar]
- 42.Shirahata T, Mori A, Ishikawa H, et al. . Strain differences of interferon-generating capacity and resistance in toxoplasma-infected mice. Microbiol Immunol. 1986;30(12):1307–1316. doi: 10.1111/j.1348-0421.1986.tb03051.x [DOI] [PubMed] [Google Scholar]
- 43.Diez B, Galdeano A, Nicolas R, et al. . Relationship between the production of interferon-alpha/beta and interferon-gamma during acute toxoplasmosis. Parasitology. 1989 Aug;99(Pt 1):11–15. doi: 10.1017/S0031182000060972 [DOI] [PubMed] [Google Scholar]
- 44.Mahmoud ME, Ui F, Salman D, et al. . Mechanisms of interferon-beta-induced inhibition of Toxoplasma gondii growth in murine macrophages and embryonic fibroblasts: role of immunity-related GTPase M1. Cell Microbiol. 2015 Jul;17(7):1069–1083. doi: 10.1111/cmi.12423 [DOI] [PubMed] [Google Scholar]
- 45.Stascheit F, Paul F, Harms L, et al. . Toxoplasma gondii seropositivity is negatively associated with multiple sclerosis. J Neuroimmunol. 2015 Aug 15;285:119–124. doi: 10.1016/j.jneuroim.2015.05.011 [DOI] [PubMed] [Google Scholar]
- 46.Oruç S, Karakaya F, Demirbas H, et al. . Relationship of Toxoplasma gondii exposure with multiple sclerosis. Eur J Gen Med. 2016;13(1):58–63. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.